



1646
FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

RECEIVED

AUG 2 2 2002

TECH CENTER 1600/2900

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

August 15, 2002

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:

August 15, 2002

Date

Steven L. Highlander

Commissioner for Patents
Washington, DC 20231


Re: *U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" by Paul B. McCray, Jr. et al.*
Our Reference: IOWA:031US
Client Reference: UIRF:M0-49

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A1, B5-B6).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted
25197861.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Paul B. McCray, Jr. et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US

RECEIVED
AUG 22 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
August 15, 2002	Date
Steven L. Highlander	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven E. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 15, 2002

Form PTO-1449 (modified)		Atty. Docket No. IOWA:031US	Serial No. 09/872,852
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Paul B. McCray, Jr. et al.	
		Filing Date: June 1, 2001	Group: 1646
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

RECEIVED

*AUG 22 2002
TECH CENTER 1600/2900*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>JHR</i>	A1	6,399,370 B1	6/4/02	Wilson et al.	435	325	1/12/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B5	DE 10033505.5	7/11/00	Germany			No
<i>JHR</i>	B6	WO 02/04487	1/17/02	PCT			Yes, Abstract only

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25197847.1

EXAMINER: *Hope Roberts* DATE CONSIDERED: *08/30/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

JP1646

PJO

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4698

July 24, 2002

RECEIVED

AUG 01 2002

TECH CENTER 1600/290

Commissioner for Patents
Washington, DC 20231

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
July 24, 2002	Date
Steven L. Highlander	

Re: U.S. Patent Application No. 09/872,852 entitled "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" by Paul B. McCray, Jr. et al.
Our Reference: IOWA:031US
Client Reference: UIRF:M0-49

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (B1-B4).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted
25189868.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Paul B. McCray, Jr. et al
Serial No.: 09/872,852
Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE



RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.	
July 24, 2002	Date
Steven L. Highlander	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231


Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 24, 2002

Form PTO-1449 (modified)

Atty. Docket No.
IOWA:031USSerial No.
09/872,852

List of Patents and Publications for Applicant's
 INFORMATION DISCLOSURE STATEMENT
 (Use several sheets if necessary)

Applicant
Paul B. McCray, Jr. et al.Filing Date:
June 1, 2001 Group:
1646U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>HAF</i>	B1	WO 00/46245	8/10/00	PCT	—	—	
	B2	WO 02/04487	1/17/02	PCT	—	—	
	B3	WO 02/09738	2/7/02	PCT	—	—	
<i>✓</i>	B4	WO 99/13080	3/18/99	PCT	—	—	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

25189853.1

EXAMINER:

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



APR 09 2002
FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/472-2020
FACSIMILE: 512/536-3184

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

1646
PH8

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

RECEIVED

APR 11 2002

April 4, 2002

TECH CENTER 1600/2900 FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R. f.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 4, 2002	Date
Steven L. Highlander	

Commissioner for Patents
Washington, DC 20231

RE: SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" – Paul B. McCray, Jr., et al. (Client Reference: URIF:M0-49)

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (C15).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl: as noted



PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:

Paul B. McCray, Jr., et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

APR 11 2002

Examiner: Unknown

TECH CENTER 1600/2900

Atty. Dkt. No.: IOWA:031US/SLH

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 4, 2002	Date
Steven Highlander	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 4, 2002

RECEIVED

APR 11 2002

TECH CENTER 1600/2900



Form PTO-1449 (modified)

**List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

Atty. Docket No. IOWA:031US/SLH	Serial No. 09/872,852
------------------------------------	--------------------------

Applicant Paul B. McCray, Jr., et al.
--

Filing Date: June 1, 2001	Group: 1646
------------------------------	----------------

U.S. Patent Documents <i>See Page 1</i>
--

Foreign Patent Documents <i>See Page 1</i>

Other Art <i>See Page 1</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>JFK</i>	C15	Co-pending U.S. Patent Application Serial Number 09/642,744 by Brian F. Tack et al., filed August 18, 2000.


25151217.1

EXAMINER:

DATE CONSIDERED:

10/30/03

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

GP/H646
1653

TELEPHONE: 512/474-5200
FACSIMILE: 512/536-3838

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM
DIRECT DIAL: 512/536-3184

RECEIVED

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

DEC 04 2001

October 29, 2001

TECH CENTER 1600/2900

FILE: IOWA:031US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 29, 2001	Date
Steven L. Highlander	

Commissioner for Patents
Washington, DC 20231

RE: SN 09/872,852 "HUMAN BETA-DEFENSIN-3 (HBD-3), A HIGHLY CATIONIC BETA-DEFENSIN ANTIMICROBIAL PEPTIDE" - Paul B. McCray, Jr., et al. (Client Reference: URIF:MO-49)

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C14).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/cmb

Encl: as noted

25087512.1



PATENT

DEC 03 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Paul B. McCray, Jr., et al.

Serial No.: 09/872,852

Filed: June 1, 2001

For: HUMAN BETA-DEFENSIN-3 (HBD-3), A
HIGHLY CATIONIC BETA-DEFENSIN
ANTIMICROBIAL PEPTIDE

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: IOWA:031US/SLH


CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

October 29, 2001

Date

Steven L. Highlander



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10104720/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 29, 2001

Form PTO-1449 (modified)		Atty. Docket No. IOWA:031US/SLH	Serial No. 09/872,852
<p style="text-align: center;">O I P E Patent & Trademark Office DEC 03 2001 Information Disclosure Statement <small>(Use several sheets if necessary)</small></p>		<p>Applicant Paul B. McCray, Jr., et al.</p>	
		Filing Date: June 1, 2001	Group: 1646
<p>U.S. Patent Documents <i>See Page 1</i></p>		<p>Foreign Patent Documents <i>See Page 1</i></p>	<p>Other Art <i>See Page 1</i></p>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>✓</i>	C1	Gallo, et al., "Antimicrobial peptides: an emerging concept in cutaneous biology," <i>J. Invest Dermatol</i> , 111(5):739-743, 1998.
	C2	Ganz and Lehrer, "Antimicrobial peptides of vertebrates," <i>Current Opinions Immun</i> , 10:41-44, 1998.
	C3	Hamil et al., "HE2β and HE2γ, new members of an epididymis-specific family of androgen-regulated proteins in the human," <i>Endocrinology</i> , 141(3): 1245-1253, 2000.
	C4	Harder et al., "Short communication—Mapping of the gene encoding human β-Defensin-2 (DEFB2) to chromosome region 8p22-p23.1," <i>Genomics</i> , 46:472-475, 1997.
	C5	Jia et al., "Discovery of new human β-defensins using a genomics-based approach," <i>Gene</i> , 263:211-218, 2001.
	C6	Kirchhoff et al., "CD52 mRNA is modulated by androgens and temperature in epididymal cell cultures," <i>Mol. Reprod. Dev.</i> , 56:26-33, 2000.
	C7	Krull et al., "Region-specific variation of gene expression in the human epididymis as revealed by in situ hybridization with tissue-specific cDNAs," <i>Mol. Reprod. Dev.</i> , 34:16-24, 1993.
<i>✓</i>	C8	Liu et al., "Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFκB, c-fos/c-jun, and p53 proteins," <i>Mol. Carcinog.</i> , 22:235-246, 1998.

25066728.1

EXAMINER:

Hope Polson DATE CONSIDERED: *10/30/03*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP009; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. IOWA:031US/SLH	Serial No. 09/872,852
<p style="text-align: center;">O P E Information Disclosure Statement List of Patents and Publications for Applicant's (Use several sheets if necessary)</p>		Applicant Paul B. McCray, Jr., et al.	
		Filing Date: June 1, 2001	Group: 1646
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C9	Mathews et al., "Production of β -defensin antimicrobial peptides by the oral mucosa and salivary glands," <i>Infect Immun.</i> , 67(6):2740-2745, 1999.
	C10	Nilsson et al., "Patient education for adults with chronic eczema," <i>Dermatol Nurs</i> , 11(2):117-122, 1999.
	C11	Oren and Shai, "Mode of action of linear amphipathic α -helical antimicrobial peptides," <i>Biopolymers</i> , 47:451-463, 1998.
	C12	Osterhoff et al., "Molecular cloning and characterization of a novel human sperm antigen (HE2) specifically expressed in the proximal epididymis," <i>Biol Reprod</i> , 50:516-525, 1994.
	C13	Russell et al., "Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha," <i>Infect Immun.</i> , 64(5):1565-1568, 1996.
✓	C14	Singh et al., "Production of β -defensins by human airway epithelia," <i>Proc. Natl. Acad. Sci USA</i> , 95:14961-14966, 1998.

25066728.1

EXAMINER: <i>Hope Robinson</i>	DATE CONSIDERED: 10 30 03
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	